Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 21 November 2013 | By Alexander Gaffney, RAC,
The Center for Biologics Evaluation and Research (CBER) has just published a new draft guidance document intended to clarify the premarket notification, or 510(k), process for certain types of test kits used to match donors and recipients during transfusions and transplantations.
The test kits in question are known as nucleic acid-based human leukocyte antigen (HLA) test kits, which are used to ensure compatibility between a donor of human cells, tissues, tissue-based products or organs and their eventual host. Non-compatible organs may be rejected by the immune system of the recipient or result in a condition known as graft-versus-host disease in which transplanted immune cells attack the new host.
The guidance comes at a time when the science behind HLA test kits is growing "increasingly complex," FDA observed.
"Testing has evolved from serology and cell-based methods with little instrumentation to deoxyribonucleic acid (DNA) based and multiplex assays that use complex instruments and software," FDA recalled. Regulators also noted the "high degree of polymorphism" and "rare phenotypes" associated with the HLA system, and said they represented "significant and unique challenges" to obtaining regulatory approval.
And those challenges can be amplified by the 510(k) submission system, which relies more on the history of similar devices to prove safety and efficacy than on new data submitted with respect to a new device.
FDA's draft guidance, Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation, makes numerous recommendations to industry.
Among them:
FDA will be accepting comments on the guidance until 18 February 2014.
Guidance
Federal Register
Tags: draft guidance
Regulatory Focus newsletters
All the biggest regulatory news and happenings.